ALFA Finder| Value | ₹3,150 Cr |
|---|
BSE filing, NSE: YATHARTH. Summary written from the filing by ALFA Finder's alert engine.
Yatharth Hospital & Trauma Care Services Ltd: key numbers
- Share price
- ₹1,046.60
- Market cap
- ₹10,084 Cr
- Revenue (annual)
- ₹1,207 Cr
- Net profit (annual)
- ₹175.4 Cr
- P/E (TTM)
- 52.9×Sector 54.5×
- Promoter holding
- 55.80%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Yatharth Hospital & Trauma Care Services Ltd
All →Yatharth Hospital & Trauma Care Services Earnings Call Transcript: Key Takeaways
Yatharth delivered record performance driven by newer acquisitions turning EBITDA positive and a strategic 3,150 Cr Advent partnership to double bed capacity.
- Call
- Guides 30% growth
Yatharth Hospital & Trauma Care Services Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 4,314 mn (+52% YoY), EBITDA Rs 1,020 mn (23.6% margin), PAT Rs 485 mn (+17% YoY). Advent Rs 3,150 cr primary infusion awaits approvals.
Yatharth Hospital & Trauma Care Services Results Update
Yatharth Hospitals reported a 52% YoY revenue growth to Rs 4,314 million for Q2 FY27. The company also announced a Rs 3,150 crore strategic investment from Advent International.
- Value
- ₹431.4 Cr
- hospital beds
- 3255.0 beds
Yatharth Hospital & Trauma Care Services Q2 FY27 Results: Net Profit ₹48.5 Cr, Up 17.4% YoY
Yatharth Hospital & Trauma Care Services Ltd reported revenue from operations of ₹431.4 Cr (+52.4% YoY) and net profit of ₹48.5 Cr (+17.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹48.5 Cr · +17.4% YoY
Yatharth Hospital & Trauma Care Services Board Meeting Date
Yatharth Hospital intimated that its Board will meet on 3 Nov 2026 to consider Q2 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
Yatharth Hospital & Trauma Care Services Annual General Meeting
Yatharth Hospital & Trauma Care Services Ltd announced the voting results for its Extraordinary General Meeting held on October 15, 2026, where all five resolutions passed.
Other preferential issue announcements
All →Aptus Pharma Preferential Issue
Aptus Pharma allotted 15,97,470 equity shares at ₹280 to 188 allottees, raising ₹44.73 Crore preferentially. Board approved the allotment on 12 November 2026.
- Value
- ₹44.73 Cr
Kirloskar Electric Company Preferential Issue
KECL received BSE and NSE listing approvals for 34,68,007 preferential issue shares to Kirloskar Power Equipments Limited. The issue value is approximately ₹40 Crore.
- Value
- ₹40.00 Cr
IIFL Finance Preferential Issue
IIFL Finance's EGM on 4 December 2026 seeks approval for a preferential issue. Convertible preference shares and warrants total about ₹6,414.20 Crore.
- Value
- ₹6,414 Cr
Natural Capsules Preferential Issue
Natural Capsules added an allotment of 1,12,500 equity shares and 4,50,000 warrants to promoter Sunil Mundra to its 13 November board agenda. No issue price is stated.
IIFL Finance Preferential Issue
IIFL Finance executed three subscription agreements for a preferential issue of CCPS and warrants at Rs 602 per share. Completion is subject to shareholder and regulatory approvals.
Simplex Infrastructures Preferential Issue
Simplex Infrastructures submitted the CARE Ratings monitoring agency report for the quarter ended 30 September 2026 on its preferential issue. The report shows nil deviation from objects, with the issue aggregating Rs.423.69 crore.